United States: Election Results Widen Gulf Between Federal V. State Regulation Of Cannabis

Legal cannabis programs continue to spread to more states with every election cycle. On Nov. 8, 2016, Arkansas, Florida, Montana and North Dakota passed laws legalizing cannabis for medical uses, while California, Nevada, Maine and Massachusetts passed laws legalizing cannabis for adult recreational use. Although each state's legislation varies, to date, more than half of states and the District of Columbia have legalized the use of cannabis for medical and/or recreational use. This latest spate of legalization only accelerates the industry's already fast-paced growth, with the Cannabis Business Times predicting that the legal cannabis market may exceed $7 billion this year.

As legal cannabis becomes more readily available to Americans, it highlights an increasingly strained divide between state and federal regulation. The federal government's position remains unchanged: Cannabis, unless approved as a new drug, is a Schedule I controlled substance and subject to criminal penalties. Despite an apparent overwhelming consensus by states that cannabis should be legalized, taxed and regulated like a business, the federal government has refused to change its position, despite its recent opportunity to do so when it rendered its decision on the cannabis descheduling petition.

Federal agencies stand strong on Schedule I

The federal government cemented its view on cannabis in August 2016 when the DEA responded to a letter from eight U.S. senators requesting the agency revisit the Schedule I status of cannabis. In its response (including Federal Reporter entries here and here), the DEA turned in large part to the FDA for information on the current state of cannabis research and its input on descheduling. In short, the FDA found that, while there are cannabis-derived drugs approved and at least two others in clinical trials, there is insufficient clinical data on the effectiveness and safety of cannabis treatments, particularly for the myriad of conditions and uses that the cannabis industry advertises. 

The DEA, after reviewing the FDA's position, adopted a similar position and refused to reschedule or deschedule cannabis. The DEA, however, did open the doors for the cannabis industry to bring reliable, clinical and scientific evidence that cannabis is safe. The DEA has now begun accepting applications from cultivation centers to become approved NIDA sources for FDA-approved cannabis research. This change notwithstanding, cannabis remains a Schedule I controlled substance.

Criminal enforcement at the state and federal level

The increasing legalization of cannabis at the state level presents a conflict between state and federal law enforcement. On one hand, the federal government views cannabis either as a drug requiring the approval process like any other drug, or as a controlled substance as defined in the Controlled Substances Act.

On the other hand, state law enforcement in states with cannabis programs must now deal with those in possession of cannabis under state standards for its legal use. Mentioned earlier, the Cole Memorandum initially set a minimum bar for states: In states with "strong and effective regulatory and enforcement systems that will address the threat those state laws could pose to public safety, public health and other law enforcement interests," and which "provide for regulation of marijuana activity and provide the necessary resources and demonstrate the willingness to enforce their laws and regulations in a manner that ensures they do not undermine federal enforcement priorities," the Department of Justice will allow local and state law enforcement agencies to address cannabis-related activity. In other words, so long as a given state has a robust cannabis regulatory system that is enforced, the DOJ will not prosecute under federal law those who adhere to state regulatory systems.

This memorandum did not carry the force of law, however, and was generally nonbinding on the DOJ. This changed in 2014 when Congress passed as part of a $1.1 trillion spending bill, the Rohrabacher-Farr medical marijuana amendment. This amendment effectively gives the Cole Memorandum the force of law, limiting the ability of the Department of Justice and the DEA to prosecute those cultivating, dispensing or in possession of medical cannabis in a manner consistent with the statutes of a state where it has been legalized. This was later affirmed by the U.S. District Court for the Northern District of California in U.S. v. Marin Alliance for Medical Marijuana, 139 F.Supp.3d 1039.

For those states that have passed laws legalizing recreational cannabis, the Cole Memorandum, which is not law, is the only thing standing between state-legal consumers, dispensaries and cultivators and federal prosecution. Furthermore, in states that have not passed any sort of cannabis legalization, the federal government is free to pursue criminal charges on anyone in contact with cannabis products.

Current state of FDA cannabis regulation

Although many states have decriminalized cannabis for various purposes, its status with the FDA has not changed. The status of cannabis as a Schedule I substance limits the FDA's ability to open new opportunities for industry members. Access to cannabis for research purposes is limited, available only through the National Institute on Drug Abuse (NIDA), and its use is subject to significant FDA oversight and security controls. To date, only two cannabis-related drugs have been approved by the FDA: Cesamet and Marinol, and two substances are undergoing clinical trials, Sativex and Epidiolex. However, outside the realm of the individual molecules used in drugs, cannabis-derived products have no current legal use in the eyes of the federal government. The FDA specifically has stated that cannabis-derived products may not be used as dietary ingredients, and as a Schedule I controlled substance, cannot be used in foods.

In February 2015 and 2016, the FDA sent warning letters to industry members making various products, including CBD oil and pet foods. Many of these warning letters contained the same message: CBD and other cannabinoids, as cannabis extracts, are not approved drugs, nor are they approved dietary ingredients and thus not appropriate for use in drug or supplement products absent an approved new drug application (NDA).

So not only has the gulf between the states and the federal agencies widened with more states legalizing cannabis, the federal agencies themselves have created their own conundrum by first taking a strong stance that cannabis continues to be a controlled substance which is illegal yet refusing to prosecute violations of that law.

Industry impact

Without a change in the federal agencies' position on cannabis, the gulf will continue to widen between state regulation and federal regulation. The answer is not and cannot be forcing the cannabis industry to file new drug applications with the FDA for use of cannabis. This very notion runs afoul of the state movement.

Although there are those who believe that if the two cannabis-based drugs in clinical trials are approved for prescription use, more new drug applications will follow, this is an expensive and time-consuming endeavor, which the states have already set aside, as evidenced by the legalization of cannabis.

The cannabis industry may have to consider forcing the federal hand by providing credible data on the safety of cannabis as it was invited to do in the DEA decision, in addition to the continuing to support the groundswell of approval at the state level. At some point, in the near future, the state regulatory position and the federal position will have to be reconciled. The industry can and should prompt that reconciliation by a clear united message to federal lawmakers. Without that, it remains unlikely that agencies, such as the FDA, will change its position on cannabis. A lack of change will inhibit market growth and prevent the cannabis industry from reaching its potential.

In addition, the uncertainties of the new administration leadership is itself contradictory. President-elect Trump has indicated most recently that he would leave regulation of cannabis to the states while some of his closest advisers have openly opposed legalization of cannabis. Ultimately, it may end up in the hands of the courts.

Thompson Coburn has a team of attorneys experienced in the regulation of FDA-controlled substances and industries, as well as consulting the cannabis industry on regulatory compliance. If you have a cannabis-related business and have any questions about this blog post or anything else related to the FDA, please feel free to contact one of our team members.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions